• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Higher plasma levels of omega-3 fatty acids not associated with worse cardiovascular outcomes compared to corn oil placebo

byJake EngelandMichael Pratte
June 2, 2021
in Cardiology, Chronic Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Eicosapentaenoic acid (EPA) levels from treatment with omega-3-fatty acids were not associated with changes in cardiovascular (CV) outcomes compared to corn oil placebo, regardless of the plasma EPA level.

2. Higher docosahexaenoic acid (DHA) plasma levels were not associated with an increase in CV events.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The evidence regarding the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on cardiovascular (CV) outcomes is mixed. The REDUCE-IT trial randomly administered EPA or mineral oil placebo and reported a reduction in CV outcomes in EPA-treated individuals. Conversely, the STRENGTH trial randomly administered omega-3-carboxylic acid (CA), which increases EPA and DHA plasma levels, or corn oil placebo and discovered no difference in CV outcomes between groups. This post hoc analysis of the STRENGTH trial evaluated the association between CV outcomes and EPA and DHA levels. There were no significant differences in CV events between the highest tertile of plasma EPA levels or the highest tertile of plasma DHA levels compared to corn oil placebo. Changes in achieved plasma EPA and DHA levels from baseline were also analyzed; there were no increases in the concentration of either fatty acid that yielded significantly more CV outcomes compared to corn oil placebo. Analysis of the STRENGTH trial demonstrated no reduction in risk for CV events from any increase or change in EPA plasma levels along with no increase in harm due to any increase or change in DHA levels. One limitation of this study, however, is that there was an association between EPA and DHA levels, which prohibits complete independent analysis of either fatty acid level.

Click to read the study in JAMA Cardiology

Relevant Reading: Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia

In-Depth [randomized controlled trial]: This was a post hoc analysis of the STRENGTH trial. The STRENGTH trial was conducted at 675 centers and enrolled 13 078 participants from October 30, 2014, to June 14, 2017. Fatty acid levels were measured at study enrollment and 12-month follow-up, and data was available at both time intervals in 10 382 participants (median [SD] age: 62.5 [8.9] years). Participants who were treated with omega-3-CA were divided into three tertiles based on plasma EPA cut-offs. The primary endpoint was a CV-related event (CV death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina requiring hospitalization). A CV event occurred in 574 out of 5207 (11.0%) participants who received corn oil and 575 out of 5175 (11.1%) treated with omega-3-CA. The highest EPA plasma level tertile (>116.4 mg/mL) experienced a CV event in 194 out of 1715 participants (11.3%; adjusted HR: 0.98; 95% CI: 0.83-1.16; p= 0.81). Omega-3-CA-treated participants were also categorized into tertiles based on plasma DHA levels. The highest DHA plasma level tertile (>105.2 mg/mL) experienced a CV event in 196 out of 1718 participants (11.4%; adjusted HR: 1.02; 95% CI: 0.86-1.20; p= 0.85).

RELATED REPORTS

Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force

Unsweetened coffee consumption is associated with reduced risk of mortality

Sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization in type 2 diabetes patients

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular diseasecardiovascular healthfatty acids
Previous Post

Maternal weight gain and pregnancy outcomes in twin gestations

Next Post

Carriers of truncated variants in filamin C with left ventricular systolic dysfunction associated with increased frequency of cardiac adverse events

RelatedReports

Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial
Cardiology

Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force

June 24, 2022
European data showed coffee consumption associated with lower mortality
Cardiology

Unsweetened coffee consumption is associated with reduced risk of mortality

June 21, 2022
Mediterranean diet linked to reduced diabetes risk in high risk cardiovascular patients
Cardiology

Sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization in type 2 diabetes patients

June 18, 2022
Early language exposure is predictive of language skills and IQ in school-age children
Cardiology

Late and moderate preterm birth associated with increased cardiometabolic risk scores in young children

June 1, 2022
Next Post
Reinnervation of cardiac infarcts decreases subsequent arrhythmia incidence [PreClinical]

Carriers of truncated variants in filamin C with left ventricular systolic dysfunction associated with increased frequency of cardiac adverse events

#VisualAbstract: Rifapentine-moxifloxacin noninferior to standard of care treatment for pulmonary tuberculosis

#VisualAbstract: Rifapentine-moxifloxacin noninferior to standard of care treatment for pulmonary tuberculosis

Quick Take: Association of Visual Impairment With Economic Development Among Chinese Schoolchildren

Primary trabeculectomy associated with similar outcomes as medical management for advanced glaucoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.